The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer. | Semantic Scholar
Optimising dose-dense regimens for early breast cancer | Cancer World Archive
Real world experience with dose dense ac-paclitaxel: Two canadian cancer centers' experience | Semantic Scholar
Trial design of AGO trial, intense dose-dense epirubicin, paclitaxel,... | Download Scientific Diagram
Optimising dose-dense regimens for early breast cancer | Cancer World Archive
Dose-Dense Adjuvant Chemotherapy “Optimal” for High-Risk Early Breast Cancer - Cancer Therapy Advisor
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials - The Lancet
Optimising dose-dense regimens for early breast cancer | Cancer World Archive
ESMO 2022: Dose-dense adjuvant chemotherapy in early-stage breast cancer patients: End-of-study results from a randomised, phase III trial of the Gruppo Italiano Mammella (GIM)
Optimising dose-dense regimens for early breast cancer | Cancer World Archive
Comparative hematological profiles for dose‑dense vs. regular anthracycline‑based neoadjuvant chemotherapy in non‑metastatic breast cancer
Dose Dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel... | Download Table
Standard vs dose-dense adjuvant chemotherapy in hormone... | Download Scientific Diagram
Dose-dense chemotherapy for breast cancer: what does the future hold? | Future Oncology
Dose-dense chemotherapy in breast cancer and lymphoma - ScienceDirect
Dose Dense-Intensive Chemotherapy Improves Survival in Early Stage Breast Cancer - CancerConnect
Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial - ScienceDirect
Dose-dense therapy is of benefit in primary treatment of ovarian cancer? In favor - ScienceDirect
外科 - dose - dense - EC - 乳腺 - q2w
Dose-dense paclitaxel plus carboplatin <i>vs</i>. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer
Adjuvant Dose-Dense Chemotherapy in Breast Cancer: Standard of Care in High-Risk Patients | Semantic Scholar
Optimising dose-dense regimens for early breast cancer | Cancer World Archive
Survival outcomes for dose‐dense paclitaxel plus carboplatin neoadjuvant vs standard adjuvant chemotherapy in stage II to III triple‐negative breast cancer: A prospective cohort study with propensity‐matched analysis - Xiu - 2022 -
乳癌 dose-dense PTX療法 - 横須賀共済病院
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin as the Gold Standard Neoadjuvant Chemotherapy Regimen for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer Remains Controversial | Journal of Clinical Oncology
Optimising dose-dense regimens for early breast cancer | Cancer World Archive
Standard vs dose-dense adjuvant chemotherapy in hormone... | Download Scientific Diagram
